Russian CRO Synergy Research Group (SynRG) relocated its business development operations to a new office in the United States in an effort to attract U.S. drug development sponsors.
The new office, based in North Kingstown, R.I., will be managed by SynRG’s new director of business development, Anna Ravdel. Prior to joining the company, Ravdel was director of business development at Evidence Clinical and Pharmaceutical Research and at Worldwide Clinical Trials.
“We have always emphasized that one of the strategic goals set by SynRG is [to enhance the] research and investment attractiveness of Russia for foreign sponsors, so business development in the U.S.A. is a natural step along this strategic line," said SynRG CEO Igor Stefanov.
Headquartered in Moscow, SynRG has offices in Russia and Kazakhstan and plans to open a Ukrainian office as well as a virtual office in Prague before the end of the year.